C07J 1/0081
Substituted in position 17 alfa and 17 beta
Official title: {Substituted in position 17 alfa and 17 beta}
C07J1/0081 (Substituted in position 17 alfa and 17 beta) appears on 184 US grants and 81 published applications in this corpus.
Search patents in C07J- Granted patents
- 184
- Published applications
- 81
- Assignees
- 78
- Inventors
- 350
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 6 | 0 |
| 1978 | 4 | 0 |
| 1979 | 6 | 0 |
| 1980 | 2 | 0 |
| 1981 | 8 | 0 |
| 1982 | 1 | 0 |
| 1983 | 3 | 0 |
| 1984 | 5 | 0 |
| 1985 | 7 | 0 |
| 1986 | 4 | 0 |
| 1987 | 3 | 0 |
| 1988 | 6 | 0 |
| 1989 | 4 | 0 |
| 1990 | 6 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 7 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 12 | 0 |
| 1999 | 6 | 0 |
| 2000 | 6 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 5 |
| 2003 | 2 | 5 |
| 2004 | 2 | 8 |
| 2005 | 3 | 5 |
| 2006 | 5 | 3 |
| 2007 | 3 | 2 |
| 2008 | 2 | 2 |
| 2009 | 0 | 0 |
| 2010 | 2 | 4 |
| 2011 | 2 | 2 |
| 2012 | 1 | 5 |
| 2013 | 1 | 2 |
| 2014 | 1 | 0 |
| 2015 | 5 | 2 |
| 2016 | 2 | 3 |
| 2017 | 2 | 2 |
| 2018 | 2 | 2 |
| 2019 | 1 | 5 |
| 2020 | 3 | 1 |
| 2021 | 5 | 9 |
| 2022 | 2 | 0 |
| 2023 | 2 | 3 |
| 2024 | 0 | 4 |
| 2025 | 2 | 4 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Orally active leukemia inhibitory factor (LIF) antagonists for the treatment of cancer29 Sep 2026US 12,747,263 B2Evestra, Inc.
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- GPX4 inhibitors and senolytic compounds and uses thereof2 Dec 2025US 12,485,132 B2Rubedo Life Sciences, Inc.
- Intermediates for the preparation of 11-methylene steroids18 Feb 2025US 12,227,537 B2Crystal Pharma, S.A.U.
- Processes for the preparation of ortho-allylated hydroxy aryl compounds24 Oct 2023US 11,795,127 B2McMaster University
- Estradiol prodrugs and methods of use thereof27 Aug 2026US 2026/0248809 A1The United States Government as represented by the Department of Veterans Affairs
- Orally Active, Brain Penetrant First-in-Class Small Molecule Midkine (MDK) Inhibitors for the Treatment of Malignancies and Non-Malignant Diseases9 Jul 2026US 2026/0191882 A1
- GPX4 Inhibitors and Senolytic Compounds and Uses Thereof8 Jan 2026US 2026/0007689 A1Rubedo Life Sciences, Inc.
- GPX4 Inhibitors and Senolytic Compounds and Uses Thereof16 Oct 2025US 2025/0319109 A1Rubedo Life Sciences, Inc.
- GPX4 Inhibitors and Senolytic Compounds and Uses Thereof25 Sep 2025US 2025/0296951 A1
Most cited
By later US patents
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995
- Estrogenic compounds as anti-angiogenic agents112US 5,504,074 AChildren's Medical Center Corporation · 1996
- Steroid derivatives61US 4,659,516 AImperial Chemical Industries PLC · 1987
- Method of treatment of androgen-related diseases48US 5,372,996 AEndorecherche, Inc. · 1994
- Estrogenic compounds as anti-mitotic agents42US 5,892,069 AChildren's Medical Center Corporation · 1999